NeuroSigma Inc: Valuation, Funding & Investors
NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy.
Leadership & Board
- Current Number of Employees
- 9
- Current LinkedIn Followers
- 680
Latest Estimated Valuation
- Total Amount Raised
- $1M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $1M
- Latest Funding Round
- Investment
Employee Trend
NeuroSigma Inc had 9 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
NeuroSigma Inc had 680 followers as of November 16, 2026. The number of followers increased by 1 (0.15%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 15, 2025 | Investment | $1.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Checkmate Capital | Investment |
Similar Companies
A snapshot of private companies similar to NeuroSigma Inc, helping you discover and navigate related company profiles.









